Dr. Nel Moore joins Board of Directors
PhagoMed today announced the appointment of Dr. Nel Moore as a Non-Executive Director. Following a European-wide search process, Dr. Moore has been selected to join PhagoMed’s Board of Directors.
Dr. Nel Moore is a global Anti-Infectives leader with deep experience in bringing novel anti-bacterials from the bench to the clinic. Nel previously led the semi-autonomous antibiotics R&D division at Astra Zeneca up and until the sale of the products to Pfizer. Within AstraZeneca she led the development, submission and approval of Zavicefta™, a combination drug for the treatment of multidrug resistant Gram-negative bacterial infections.
Nel advises numerous companies incl. as chair of the board of directors at Chain Biotech. In addition, Nel chairs the Advisory, and Post-Award Advisory boards of CARB-X. Nel studied medical biochemistry and holds a PhD from the University of Birmingham.
“As our lead programs mature, we are looking to bring additional pharmaceutical and clinical drug development expertise to our team. Therefore, we are excited that Nel has joined our board. She has decades-long experience in developing novel therapeutics and her expertise will be a great benefit for us as our programs move closer to the clinic.” says Dr. Lorenzo Corsini, Co-CEO of PhagoMed.